The path from promising scientific insight to an Investigational New Drug (IND) application is both exhilarating and unforgiving. Regardless of how breakthrough the science may be, success depends on ...
Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish Pharma’s ambitious restructuring. This morning’s third-quarter earnings ...
AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage ...
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy ...
Kodiak (KOD) is a clinical phase biotech focused on retinal diseases, with a compact, but promising late-stage pipeline. The company currently has three molecules in late stage clinical trials, ...
BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human ...
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results